CTOR

시간 외 거래: 1.46 -0.02 -1.35%

Citius Oncology Inc (CTOR)

개요 뉴스 가격 이력 토론 예측

Relative Volume:

Citius Oncology Inc Stock (CTOR) Company Profile

Citius Oncology Inc

Healthcare (1161)

(908) 967-6677

11 COMMERCE DRIVE, CRANFORD

최신 SEC 제출 서류

CTOR's Discussions on Twitter

CTOR을(를) 다른 주식과 비교

주식	가격	시가총액	매출	순이익	현금흐름	주당 순 이익
CTOR Citius Oncology Inc	1.48	138.81M	0	0	0	0.00
ZTS Zoetis Inc	147.37	69.30B	9.29B	2.52B	2.28B	5.57
TAK Takeda Pharmaceutical Co Adr	14.44	47.50B	30.08B	710.16M	4.45B	0.2182
HLN Haleon Plc Adr	9.53	44.47B	14.35B	1.85B	0	0.4023
TEVA Teva Pharmaceutical Industries Ltd Adr	16.31	18.83B	16.54B	-1.64B	749.00M	-1.45
UTHR United Therapeutics Corp	293.12	13.43B	2.99B	1.21B	1.13B	25.06

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

날짜	액션	분석자	등급 변경
2024-11-27	개시	Maxim Group	Buy

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Citius Oncology Inc (CTOR) 재무 분석

Citius Oncology Inc (CTOR)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.

Citius Oncology Inc (CTOR)

Citius Oncology Inc Stock (CTOR) Company Profile

CTOR을(를) 다른 주식과 비교

Citius Oncology Inc Stock (CTOR) Upgrades & Downgrades

Citius Oncology Inc 주식(CTOR)의 최신 뉴스

Is Citius Oncology Inc. a good long term investmentExponential wealth increase - Autocar Professional

What analysts say about Citius Oncology Inc. stockHigh-velocity gains - Autocar Professional

What drives Citius Oncology Inc. stock pricePowerful profit generation - Autocar Professional

Citius Oncology Announces Closing of $9.0 Million Public Offering - Eastern Progress

Citius Oncology shares rise 1.31% after-hours after closing a $9.0 million public offering. - AInvest

Should I buy Citius Oncology Inc. stock before earningsShort Term High Return Strategy - Newser

Citius Oncology Completes $9M Public Offering - TipRanks

Citius Oncology Inc. Stock Analysis and ForecastDynamic profit expansion - jammulinksnews.com

Citius Oncology launches $15M equity and warrant offering; shares down - MSN

Citius Oncology closes $9 million public offering to support LYMPHIR - Investing.com Australia

Citius Oncology closes $9 million public offering to support LYMPHIR By Investing.com - Investing.com South Africa

Citius Oncology Raises $9M in Public Offering for LYMPHIR Commercialization - AInvest

Citius Oncology Announces Closing Of $9.0 Million Public Offering - Barchart.com

Citius Oncology Announces Pricing Of $9M "Reasonable Best-Efforts" Public Offering Of 6,818,182 Shares Of Common Stock And Warrants To Purchase Shares Of Common Stock At A Public Offering Price Of $1.32 Per Share - 富途牛牛

Citius Pharmaceuticals shares fall 1.34% after-hours following Citius Oncology's public offering. - AInvest

Citius Oncology’s Chances: Time to Invest? - StocksToTrade

Citius Oncology Announces Pricing of $9.0 Million Public Offering - PR Newswire

Citius Oncology Soars 35.06% on Distribution Deal - AInvest

Citius Oncology Soars 12.34% on Expanded Lymphir Distribution - AInvest

Citius Oncology stock rises after expanding LYMPHIR distribution network - Investing.com

What makes Citius Oncology Inc. stock price move sharplySecure Your Capital Strategy - Newser

Why Citius Oncology Inc. stock attracts strong analyst attentionEarly Breakout Tracker - Newser

Cencora (COR) Partners With Citius Oncology For Immunotherapy Distribution Expansion - simplywall.st

Citius Oncology Shares Climb Following Expansion of LYMPHIR Distribution Network - MSN

Citius Oncology (CTOR): Is LYMPHIR's Launch Priced for Success? - AInvest

Citius Oncology: Is A Lymphir Launch Coming Too Late? - Seeking Alpha

Citius Pharmaceuticals (CTXR) Surges on New Distribution Deal - GuruFocus

Citius Oncology stock rises after expanding LYMPHIR distribution network By Investing.com - Investing.com South Africa

How Citius Oncology Inc. stock performs during market volatilityLow Risk Entry Points - Newser

Citius Oncology Expands Lymphir Distribution With Cencora - MarketScreener

Cencora distribution deal boosts Citius shares - MSN

Citius Oncology expands distribution network for LYMPHIR with Cencora - Investing.com Australia

Citius Oncology expands distribution network for LYMPHIR with Cencora By Investing.com - Investing.com India

Citius stock gains on Cencora distribution deal (CTXR:NASDAQ) - Seeking Alpha

Citius Oncology Expands Distribution Network for LYMPHIR with Execution of Distribution Services Agreement with Cencora - Finansavisen

Citius Oncology shares rise 4.64% after-hours despite plans for stock offering. - AInvest

CTOR Crashes 34%—Is This the Breaking Point for Citius Oncology? - AInvest

Citius Oncology Plans Stock Offering; Shares Down - MarketScreener

Citius Oncology seeks $15M to fund LYMPHIR launch amid going-concern risk | TENKU SEC FilingForm S-1 - Stock Titan

Anchoring Your Portfolio: Is CTOR Stock a Safe Harbor? - investchronicle.com

Citius Pharmaceuticals regains Nasdaq compliance - MSN

Amid NCI Budget Fears, Emerging Oncology Stocks Gain Attention - PentictonNow

Citius Pharmaceuticals regains Nasdaq compliance after 10-day streak - Investing.com

Citius Pharma Dodges Delisting: Stock Maintains $1+ Price for 10 Straight Days, Secures Nasdaq Future - Stock Titan

Citius Pharmaceuticals: LYMPHIR Launch Ignites High-Growth Potential in CTCL Market - AInvest

Citius Oncology Inc (CTOR) 재무 분석

매출

순이익

현금흐름

주당 순 이익

CTOR과 유사한 종목